Innovative Treatment in Aplastic Anemia and Other Inherited Bone Marrow Failure Syndromes

Treatment approaches for aplastic anemia (AA) and inherited bone marrow failure syndromes (IBMFS) have evolved significantly, changing how doctors approach initial treatment, transplant decisions, and research directions. For patients with acquired severe AA (SAA), adding eltrombopag, a drug that stimulates platelet production, to the standard combination of anti-thymocyte globulin and cyclosporine has revolutionized immunosuppressive treatment. This approach speeds up blood cell recovery across all three cell lines and improves complete response rates, with survival rates now exceeding 90% in recent studies. Using eltrombopag with cyclosporine alone provides a practical alternative in areas with limited resources, though doctors must remain watchful for abnormal cell changes. At the same time, stem cell transplantation has become more widely available. Transplants using half-matched family donors with post-transplant cyclophosphamide now achieve survival rates similar to those with fully matched unrelated donors. Safety improvements come from using fludarabine-based gentler conditioning regimens, preferring bone marrow over other graft sources, wider use of post-transplant cyclophosphamide to prevent graft-versus-host disease, and letermovir to prevent CMV infections. Doctors increasingly consider upfront transplants from alternative donors for very severe cases or when immunosuppressive therapy fails. For inherited syndromes, advances target specific conditions. In Fanconi anemia, new conditioning approaches using only antibodies against CD117 reduce harmful radiation exposure. Laboratory-based gene therapy using modified viruses has shown lasting blood improvements without conditioning, while newer gene editing techniques and messenger RNA approaches continue developing. For patients with dyskeratosis congenita and related telomere disorders, specialized reduced-intensity conditioning with alemtuzumab minimizes organ damage. Androgen medications can lengthen telomeres, anti-scarring drugs help lung problems, and early gene therapy targeting telomerase shows promise, differing from Fanconi anemia’s focus on blood cell correction. Shwachman Diamond syndrome care now includes genetic monitoring of TP53 and EIF6 changes to schedule transplants before cancer develops, with laboratory studies exploring ways to modify these genetic pathways. Diamond-Blackfan anemia treatment incorporates L-leucine as a supportive therapy and includes experimental RPS19 gene therapy programs, while transplantation remains the cure for treatment-resistant cases. In GATA2 deficiency, earlier transplantation addresses both bone marrow problems and immune system weakness, often improving HPV-related disease and lung complications. Family members must be screened for genetic variants before serving as donors. These developments allow for personalized treatment plans: enhanced immunosuppressive therapy with thrombopoietin receptor agonists or early curative transplantation for severe aplastic anemia, and condition-specific transplant, drug, and genetic treatments for inherited syndromes. The goal remains maximizing cure rates while minimizing treatment toxicity and long-term complications.